Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure
The purpose of this study is to assess the response rate at 6 months in Myelodysplastic Syndrome (MDS) patients, Chronic Myelomonocytic Leukaemia (CMML-2) patients, and Acute Myeloid Leukaemia (AML) patients with up to 30% bone marrow blasts, treated with low-dose decitabine who have previously failed therapy with 5-azacitidine.
Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome
DRUG: Decitabine
Overall response rate in the efficacy-evaluable (EE) population, 6 months
Overall survival, 18 months|Time to AML progression (for MDS and CMML-2 patients only) or death, 18 months|Haematological improvement, 18 months|Transfusion requirements, 18 months|Cytogenetic response, 18 months|Treatment related toxicity, Up until one month after last IMP dose
The purpose of this study is to assess the response rate at 6 months in Myelodysplastic Syndrome (MDS) patients, Chronic Myelomonocytic Leukaemia (CMML-2) patients, and Acute Myeloid Leukaemia (AML) patients with up to 30% bone marrow blasts, treated with low-dose decitabine who have previously failed therapy with 5-azacitidine.